Application of Blood Group Genotyping by Next-Generation Sequencing in Various Immunohaematology Cases
Transfusion Medicine and Hemotherapy · 2022 · 49 (2) · 88-97
DOI: 10.1159/000517565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 11.08.2021. Verfasst von Tae Yeul Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Next-generation sequencing (NGS) technology has been recently introduced into blood group genotyping; however, there are few studies using NGS-based blood group genotyping in real-world clinical settings. In this study, we applied NGS-based blood group genotyping into various immunohaematology cases encountered in routine clinical practice.
Methods
This study included 4 immunohaematology cases: ABO subgroup, ABO chimerism, antibody to a high-frequency antigen (HFA), and anti-CD47 interference. We designed a hybridization capture-based NGS panel targeting 39 blood group-related genes and applied it to the 4 cases.
Results
NGS analysis revealed a novel intronic variant (NM_020469.3:c.29-10T>G) in a patient with an Ael phenotype and detected a small fraction of ABO*A1.02 (approximately 3–6%) coexisting with the major genotype ABO*B.01/O.01.02 in dizygotic twins. In addition, NGS analysis found a homozygous stop-gain variant (NM_004827.3:c.376C>T, p.Gln126*; ABCG2*01N.01) in a patient with an antibody to an HFA; consequently, this patient’s phenotype was predicted as Jr(a−). Lastly, blood group phenotypes predicted by NGS were concordant with those determined by serology in 2 patients treated with anti-CD47 drugs.
Conclusion
NGS-based blood group genotyping can be used for identifying ABO subgroup alleles, low levels of blood group chimerism, and antibodies to HFAs. Furthermore, it can be applied to extended blood group antigen matching for patients treated with anti-CD47 drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
- Stem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea.
- Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, Republic of Korea.
Zitieren
APA
Kim, T. Y., Yu, H., Phan, M. T., Jang, J. H., & Cho, D. (2022). Application of Blood Group Genotyping by Next-Generation Sequencing in Various Immunohaematology Cases. Transfusion Medicine and Hemotherapy, 49(2), 88-97. https://doi.org/10.1159/000517565
Vancouver
Kim TY, Yu H, Phan MT, Jang JH, Cho D. Application of Blood Group Genotyping by Next-Generation Sequencing in Various Immunohaematology Cases. Transfusion Medicine and Hemotherapy. 2022;49(2):88-97. doi:10.1159/000517565
BibTeX
@article{Kim2022,
author = {Kim, Tae Yeul and Yu, HongBi and Phan, Minh-Trang Thi and Jang, Ja-Hyun and Cho, Duck},
title = {Application of Blood Group Genotyping by Next-Generation Sequencing in Various Immunohaematology Cases},
journal = {Transfusion Medicine and Hemotherapy},
year = {2022},
volume = {49},
number = {2},
pages = {88--97},
doi = {10.1159/000517565}
}
EUVIMED